TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05669430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251
Description: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251
Description: GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251 and Pembrolizumab [KEYTRUDA®]
Description: GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251 and Pembrolizumab [KEYTRUDA®]
Description: GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
Study: NCT04984473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
Study: NCT06320431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Thrombolytic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Thrombolytic
Study: NCT05759624

Intervention type: DRUG
Intervention: rhGH
Description: Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
Study: NCT06472531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INR101
Description: • 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INR101
Description: * 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Study: NCT05789589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Patients will undergo standard of care SRS as per the treating facility's policies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT).
Study: NCT04919824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection
Description: Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection
Description: Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
Study: NCT06411600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
Study: NCT06384001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active MBM
Description: The MBM is designed to be applied for 20 minutes per session daily for two weeks. The recording will instruct participants to close their eyes, connect to the openness of one's minds, and mindfully maintain and deepen the connection through breathing with more openness and awareness. The MBM intervention will include three recordings that gradually take the participant into a more profound meditation practice. Participants will be instructed to listen to Meditation 1 for the first three days of the intervention, then switch to Meditation 2 for days 4-6 and Meditation 3 for the remainder of the 2-week intervention. The participants will be asked to practice meditation for eight weeks (6 weeks after the initial two weeks of MBM practice).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham MBM
Description: The sham MBM intervention was also recorded. The sham recording will instruct participants to relax and take deep breaths every 3 minutes without the specific mindfulness-based instructions (e.g., practicing mindful attention to the breath in a non-evaluative manner). All other aspects of the sham MBM intervention (e.g., body position, time spent listening to instructions, eyes closed) will match the active MBM.
Study: NCT05390528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX301
Description: HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
Study: NCT06421675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab injection
Description: Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
Study: NCT06189157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
Study: NCT06643364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vision Training Program
Description: Vision Training Programme: A training programme including exercises such as saccadic movements of the eye, spiral movements, converging-diverging exercises, peripheral walking was applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Training Program
Description: All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Training Program
Description: All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
Study: NCT05994521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP alone
Description: ERCP with biliary stenting will be performed alone. ERCP is part of standard of care for biliary drainage. An endoscope is advanced to the small intestines and a metal stent is inserted through the tumor instead of bypassing the tumor to effectively drain the biliary system under x-ray guidance.~Management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP +ProEUS-GE
Description: ERCP is performed as described above. following the ERCP, the scoped is switched for an echoendoscope which is advanced to the stomach. A stent is then placed between the stomach and the small intestines, creating a connection (ProEUS-GE).
Study: NCT05427760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
Study: NCT05195918

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 300 mg + Nintedanib
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 300 mg + Pirfenidone
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2 capsules + Nintedanib or Pirfenidone
Description: Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 600 mg + Nintedanib
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG 600 mg + Pirfenidone
Description: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4 capsules + Nintedanib or Pirfenidone
Description: Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone
Study: NCT04738890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
Study: NCT06140563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation dosing
Description: In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation dosing
Description: In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
Study: NCT06250647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin K diet
Description: 500mcg of Vitamin K intake provided by the selection of vitamin k rich foods in the menu.
Study: NCT06327763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ilioinguinal nerve section
Description: patients operated on by open inguinal hernioplasty with ilioinguinal neurectomy
Study: NCT05890898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.
Study: NCT05309460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Oral Tablet
Description: See Labetalol arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: See Nifedipine arm.
Study: NCT06180941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate.
Description: magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine.
Description: clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Study: NCT05719623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CUEVAS MEDEK EXERCISES
Description: stretchings/strengthening

Intervention type: OTHER
Group type: OTHER
Intervention: BALANCE AND POSTURAL
Description: BALANCE AND POSTURAL
Study: NCT05815901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epaminurad 6 mg
Description: Epaminurad 6 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epaminurad 9 mg
Description: Epaminurad 9 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat 40 mg
Description: Febuxostat 40 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat 80 mg
Description: Febuxostat 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epaminurad 6 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epaminurad 6 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epaminurad 6 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epaminurad 9 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epaminurad 9 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epaminurad 9 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat 40 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat 80 mg placebo
Description: Placebo tablet
Study: NCT05287516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast meal
Description: A meal consisting of breakfast biscuits and water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast meal
Description: A meal consisting of breakfast biscuits and water.
Study: NCT05510635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive bibliotherapy
Description: The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reading bibliotherapy
Description: The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
Study: NCT05983120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educate the patients who suffer from Type 2 Diabetes Mellitus
Study: NCT05202990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation by Stool capsules
Description: After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation by Intra-rectal enemas
Description: After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas.
Study: NCT05413369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide
Description: solution, by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDegAsp
Description: solution, by subcutaneous injection
Study: NCT05492812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation and Nursing Management in EEG Recording in Children
Description: Evaluation of the effect of sedative agents applied during EEG recording in children

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation and Nursing Management in EEG Recording in Children
Description: Evaluation of the effect of sedative agents applied during EEG recording in children

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation and Nursing Management in EEG Recording in Children
Description: Evaluation of the effect of sedative agents applied during EEG recording in children
Study: NCT05413369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Tablet, orally
Study: NCT05956158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment
Description: This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Treatment
Description: This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
Study: NCT06354998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational mRNA-1273.815
Description: Sterile solution for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Spikevax Vaccine
Description: Commercially available formulation
Study: NCT05346211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin Supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin Supplementation
Study: NCT04172012

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Labinic (R) probiotic mixture
Description: Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mixture